Navigation Links
Annual Shareholders Meeting to Be Held May 5, 2008 at the University Club in St. Paul, MN
Date:4/15/2008

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it will hold its annual shareholders meeting at 9:00 AM on May 5, 2008 at the University Club in St. Paul, MN.

Shareholders who held SpectraScience stock as of the close of business on March 31, 2008 and those who hold a valid proxy for the meeting are entitled to attend in person.

Jim Hitchin, CEO of SpectraScience, Inc. said, "I look forward to meeting with our shareholders to talk about our recent historical results and our plans for the future."

Additional information, including details of the business to be conducted at the annual meeting, is included in the Company's Notice of Annual Meeting of Shareholders and Proxy Statement, which has been filed with the Securities and Exchange Commission and mailed to all shareholders of record.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT(R) Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA(R) cervical imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

Contact:

SpectraScience, Inc.

Jim Hitchin, Chief Executive Officer

(858) 847-0200 x201

http://www.spectrascience.com

Hayden Communications

Investor Relations

Todd Pitcher

(858) 518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cedar Point to Host 17th Annual Red Cross Miniature Golf Event
2. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
3. Otter Tail Corporation Holds 2008 Annual Meeting: Shareholders Elect Directors; Board Declares Quarterly Dividend
4. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
5. Northwest Hospital & Medical Center Hosts Health & Wellness Pavilion At Second Annual King 5 Healthy Living Expo
6. European Society of Human Reproduction & Embryology 24th annual meeting
7. Media advisory - Neurochems Annual and Special Meeting of Shareholders April 15, 2008
8. Neurochem Annual and Special Meeting of shareholders
9. With annual deaths from malaria on the rise: Scientists ask where is all the money going?
10. China Medical Technologies to Announce 4QFY2007 Financial Results, Declare Annual Cash Dividend and Provide FY2008 Annual Targets on June 12, 2008
11. HealthMEDX Hosts Annual User Group Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... Walk with God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true ... How to Walk with God #TruthwithGrace” is the creation of published author Lea ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion ... real people of God in congregations across the United States. “The Communion ... ordained in 1964 who has served congregations in seven states throughout his long ...
(Date:3/23/2017)... Boulder, CO (PRWEB) , ... March 23, 2017 , ... ... higher bar for entry into teacher preparation programs. The NCTQ report suggests, based on ... boosting entry requirements would significantly improve teacher quality in the U.S. It argues that ...
(Date:3/23/2017)... New Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... a new clinic, located at 960 Gruene Road in Building 2. The clinic is ... co-owner Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings ...
(Date:3/23/2017)... Holland, PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI ... the modular industry or whose acts have had a significant impact on the careers of ... Sales and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017  Mirabilis Medical, a Seattle ... non-invasive surgery, announced today CE Mark authorization for ... uterine fibroids throughout the European Union.  The company ... the US Food and Drug Administration to begin ... the United States.  The Mirabilis System combines high-speed ...
(Date:3/24/2017)... and GENEVA , March 24, 2017 ... Tuberculosis Day revitalizes efforts to develop sutezolid as effective ... World Tuberculosis Day, TB Alliance and the Medicines Patent ... development of sutezolid, an antibiotic drug candidate which demonstrated ... the development of sutezolid in combination with other TB ...
(Date:3/23/2017)... , Mar 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $3.5 billion ... and forecasts for all the given segments on global as well ...
Breaking Medicine Technology: